Bin Huang, Ph.D., MBA

President and CEO, Emerald Health Therapeutics

Dr. Huang is an executive leader with over 30 years of experience in life sciences. Her career began with Allelix Crop Technologies, where she spent six years as a plant research scientist. For a number of years, Dr. Huang was the President and CEO of Cytovax Biotechnologies, a Canadian biotechnology company. Following that, she led WEX Pharmaceuticals, a subsidiary of publicly listed CK Life Sciences International (Holdings) Inc., as President and CEO. Dr. Huang has a Ph.D. in Plant Cell Biology from the University of East Anglia, UK and an MBA from the University of Toronto.

Madi Madiyalakan, Ph.D.

OncoQuest Chief Executive Officer

Dr. Madiyalakan is the CEO of OncoQuest and also the CEO of Quest PharmaTech since August 2006; and Director since July 2004. He was one of the founders of SonoLight Pharmaceuticals Corp. (served as its CEO and Director), CanBiocin Inc. (served as President, CEO and Director) and AltaRex Corp. (served as Vice-President, Planning and Chief Scientific Officer). Between 1987 and 1995 Dr. Madiyalakan served in various senior positions at Biomira Inc. Dr. Madiyalakan holds a Masters (Chemistry) and Ph.D. (Biochemistry) and a Certificate in Management Development. In addition, he has over 25 years of academic and industrial research experience on an international basis. He has published extensively and been an inventor of several patents.

Shawn Lu, MBA, CCA

CFO, Hepalink USA

Mr. Shawn Lu, CIM, MFin, has been the Chief Financial Officer of Hepalink USA Inc., since 2014. From 2013 to 2014, Mr. Lu served as an Area Manager for BMO Bank of Montreal in the central Greater Toronto area. From 2005 to 2013, he worked with the TD Bank as a Residential Mortgage Manager in North York, Toronto. From 2001 to 2005, he served as a Senior Financial Advisor for TD Bank in Toronto. From 1999 to 2000, he was employed with ShenZhen Hepalink Biopharmaceutical Co., Ltd as the Chief Financial Officer and Vice President of Corporate Finance. From 1998 to 1999, he served as the Vice President of Investment and Corporate Finance at Shen Zhen Fu Tian Xin Investment Co., Ltd. From 1992 to 1998, he served as the General Manager of Corporate Finance Department and Manager of Investment & Finance Department at China Merchant Shekou Port Co. Ltd., (a Shenzhen Stock Exchange listed company). He has extensive experience in the areas of corporate finance, capital markets and investment financing. He has been a Director of Hepalink USA Inc. since 2014; Resverlogix Corp. since April 2, 2016; Quest PharmaTech, Inc. since December 1, 2015, and Hepalink USA Inc. since 2014. He has a Canadian Investment Manager (CIM, Canada) designation. Mr. Lu also holds a Certified Accountant and Certified Corporate Economist designation in China. He holds a Master of Finance Management from Queens University, School of Business, Kingston, Ontario., and a Master of Corporate Economics and Business Administration from Zhong Nan University, Wuhan, China.

Xiangyu Gong, MBA

Vice President, Process and IT Management, Shenzhen Hepalink Pharmaceutical

Mr. Gong has 30 years working experience in the electronics and biopharmaceutical industries and is currently the Vice President - Process and IT Management for Shenzhen Hepalink Pharmaceutical Co. Ltd, Shenzhen, China, a pharmaceutical company listed on the ShenZhen Stock Exchange. Mr. Gong worked as the Director of Operations and Planning Manager for Shenzhen Joyside Industrial Co., Ltd from 2007 to 2011 and was Senior Director of Display Technology for Philips Electronics Co., Ltd, Shanghai, from 2001 to 2007. He has a Masters in Business Administration from the China Europe International Business School, China.

Paul Van Damme, C.A.

CFO Structural Genomics Consortium (SGC)

Mr. Van Damme has served in senior financial roles for a number of public companies in both the United States and Canada. He joined Laidlaw Inc. and helped implement their expansion into Europe. After three years as Chief Financial Officer of TeleZone, a start-up wireless telecommunications company, he became CFO of a private biotech firm and helped raise venture financing to expand its product portfolio. Mr. Van Damme later joined Allelix Pharmaceuticals Inc. and participated in the merger of the company with NPS Pharmaceuticals of Salt Lake City. He has also been CFO of Lorus Therapeutics, Vasogen and Bradmer Pharmaceuticals. He is currently the CFO of Structural Genomics Consortium, a pubic private partnership.

He also serves as a Director and Chair of the Audit Committee of XORTX Therapeutics.